ADR Biomedical Holdings (3750) Earnings: Sales Surge +840.0% YoY to 57,000,000 JPY

ADR Biomedical Holdings (3750) has released its financial results, reporting a significant top-line expansion with sales surging +840.0% year-on-year to 57,000,000 JPY. However, the company posted an operating loss of 91,000,000 JPY, an ordinary loss of 93,000,000 JPY, and a net loss attributable to owners of the parent of 93,000,000 JPY. Earnings per share (EPS) stood at -10.49 JPY.

Analyzing the financial structure and profitability metrics, the equity ratio is currently at -19.7%, indicating a need to monitor balance sheet stability. While interest-bearing debt is reported at 0.2 billion JPY, retained earnings remain in a deficit of 3.02 billion JPY. Furthermore, ROE stands at -179.98% and ROA at -20.32%, as market participants keep a close eye on the path toward profitability.

---

Correction (September 20, 2026): the equity ratio was corrected to the value in the original disclosure (tanshin 140120260630584849).